Noubar Afeyan Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $108.32, for a total transaction of $1,624,800.00. Following the completion of the transaction, the director now directly owns 2,041,931 shares in the company, valued at $221,181,965.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total transaction of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Stock Performance

Shares of MRNA stock opened at $107.97 on Friday. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The stock has a market cap of $41.34 billion, a PE ratio of -8.70 and a beta of 1.62. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average price is $102.54 and its 200-day moving average price is $93.70.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna’s revenue was down 44.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.61 EPS. On average, equities analysts expect that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MRNA. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 2nd. Canaccord Genuity Group boosted their price objective on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Royal Bank of Canada reissued an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Finally, HSBC reissued a “reduce” rating and set a $86.00 price objective (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $126.49.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently bought and sold shares of the company. UMB Bank n.a. boosted its stake in Moderna by 121.8% in the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock worth $39,000 after purchasing an additional 201 shares in the last quarter. Center for Financial Planning Inc. boosted its stake in Moderna by 243.1% in the 1st quarter. Center for Financial Planning Inc. now owns 988 shares of the company’s stock worth $105,000 after purchasing an additional 700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Moderna by 13.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 133,247 shares of the company’s stock worth $14,199,000 after purchasing an additional 15,611 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in Moderna by 5.0% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 50,430 shares of the company’s stock worth $5,374,000 after purchasing an additional 2,400 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in Moderna by 11.2% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 25,786 shares of the company’s stock worth $2,748,000 after purchasing an additional 2,605 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.